START New Jersey — East Brunswick, New Jersey

START New Jersey is a clinical research site located in East Brunswick, New Jersey, United States 08816.

Crixeo Clinical Trials Trust Score: 18/100 (FAILING). This profile has not yet been claimed by the site owner.

START New Jersey has participated in 9 clinical trials with 9 currently active.

Therapeutic areas: Relapsed/Refractory Hematological Malignancies, Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL, Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL; Including Richter Transformation).

Sponsors: Ascentage Pharma Group Inc., Duboce Biopharmaceuticals, Inc., Verastem, Inc..

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in East Brunswick

Browse all research sites in New Jersey · View every site in East Brunswick

Sponsor Feasibility Report

Trust Score: 18/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for START New Jersey?

START New Jersey has a Crixeo Trust Score of 18/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has START New Jersey conducted?

START New Jersey has 9 clinical trials on record, with 9 currently active. Their work covers Relapsed/Refractory Hematological Malignancies, Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL, Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL; Including Richter Transformation).

Is START New Jersey accredited by Crixeo Clinical Trials?

START New Jersey has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about START New Jersey?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.